Citadel Advisors
SRNE

Citadel Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Citadel Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-209,800
Closed -$186K – 16112
2022
Q4 		$186K Buy
209,800
+108,800
+108% +$144K ﹤0.01% 10260
2022
Q3 		$159K Sell
101,000
-118,000
-54% -$268K ﹤0.01% 10649
2022
Q2 		$440K Buy
219,000
+67,300
+44% +$116K ﹤0.01% 8936
2022
Q1 		$353K Sell
151,700
-365,000
-71% -$1.14M ﹤0.01% 10213
2021
Q4 		$2.4M Sell
516,700
-126,900
-20% -$788K ﹤0.01% 5816
2021
Q3 		$4.91M Sell
643,600
-205,200
-24% -$1.74M ﹤0.01% 4334
2021
Q2 		$8.22M Buy
848,800
+316,300
+59% +$2.52M ﹤0.01% 3427
2021
Q1 		$4.4M Sell
532,500
-132,600
-20% -$1.4M ﹤0.01% 4547
2020
Q4 		$4.54M Buy
665,100
+153,400
+30% +$1.23M ﹤0.01% 3855
2020
Q3 		$5.71M Buy
511,700
+253,200
+98% +$2.32M ﹤0.01% 2968
2020
Q2 		$1.62M Buy
258,500
+194,200
+302% +$743K ﹤0.01% 4932
2020
Q1 		$118K Buy
64,300
+28,600
+80% +$82.4K ﹤0.01% 8517
2019
Q4 		$121K Buy
35,700
+17,400
+95% +$41.5K ﹤0.01% 8472
2019
Q3 		$39K Sell
18,300
-28,800
-61% -$67.1K ﹤0.01% 8781
2019
Q2 		$126K Buy
47,100
+9,600
+26% +$34.5K ﹤0.01% 8440
2019
Q1 		$178K Buy
37,500
+11,100
+42% +$29.1K ﹤0.01% 8292
2018
Q4 		$63K Sell
26,400
-500
-2% -$1.63K ﹤0.01% 8424
2018
Q3 		$118K Buy
26,900
+14,800
+122% +$82K ﹤0.01% 8506
2018
Q2 		$87K Sell
12,100
-22,700
-65% -$154K ﹤0.01% 8297
2018
Q1 		$179K Buy
+34,800
New +$248K ﹤0.01% 7434
2016
Q1 		– Sell
-2,400
Closed -$21K – 8301
2015
Q4 		$21K Sell
2,400
-2,900
-55% -$24.5K ﹤0.01% 7900
2015
Q3 		$44K Buy
5,300
+1,700
+47% +$27.1K ﹤0.01% 7673
2015
Q2 		$63K Buy
3,600
+3,200
+800% +$41.1K ﹤0.01% 7498
2015
Q1 		$5K Buy
+400
New +$4.63K ﹤0.01% 8331

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Citadel Advisors's SRNE Position: Q1 2023 in Review

Citadel Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 200,096 shares — an estimated $177K sold.

Citadel Advisors first reported a position in SRNE in Q1 2015 and held it in 26 quarters. The position peaked at $4.77M in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Citadel Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 200,096 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $177K.
  • Citadel Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 26 quarters.
  • Citadel Advisors's Sorrento Therapeutics, Inc. position peaked at $4.77M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.